A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)

Author(s): Brent N. Reed, Carla A. Sueta.

Journal Name: Current Cardiology Reviews

Volume 11 , Issue 1 , 2015

Submit Manuscript
Submit Proposal

Graphical Abstract:


This review will outline the management of patients with symptomatic systolic heart failure or heart failure with reduced ejection fraction (HFrEF), i.e., those with structural heart disease and previous or current symptoms. Determination of volume status and appropriate diuretic administration is important in heart failure management. Inhibition of the renin-angiotensin-aldosterone and sympathetic nervous systems improves survival and decreases hospitalizations in patients with systolic or reduced ejection fraction HF (HFrEF). Beta blockers and aldosterone antagonists improve ejection fraction. Indications for additional agents including nitrates plus hydralazine, digoxin, statins, omega 3 polyunsaturated fatty acids, anticoagulants, and antiarrhythmics will be discussed. Choice of agents, dose-related effects, strategies to minimize adverse effects, and medications to avoid will be presented.

Keywords: ACE inhibitor, aldosterone antagonist, angiotensin receptor blocker, beta blocker, heart failure with reduced ejection fraction, systolic heart failure.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [23 - 32]
Pages: 10
DOI: 10.2174/1574884708666131117125508

Article Metrics

PDF: 111